The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy

International Journal of Biochemistry and Cell Biology

Volumn 64, Issue , 2015, Pages 185-189

  Tarallo, Valeria ^a   De Falco, Sandro ^a,b  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Anti angiogenesis therapy; Cancer; Ocular neovascular diseases; VEGF family

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; ARTICLE; DRUG TARGETING; EYE DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OCULAR NEOVASCULAR DISEASE; PROTEIN FAMILY; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84928953472     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2015.04.008     Document Type: Short Survey

References (36)

1. R.J. Albuquerque The newest member of the VEGF family Blood 121 2013 4015 4016
2. J. Ambati, and B.J. Fowler Mechanisms of age-related macular degeneration Neuron 75 2012 26 39
3. L. Bellik, M.C. Vinci, S. Filippi, F. Ledda, and A. Parenti Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia Br J Pharmacol 146 2005 568 575
4. P.A. Campochiaro Retinal and choroidal neovascularization J Cell Physiol 184 2000 301 310
5. K.K. Ciombor, J. Berlin, and E. Chan Aflibercept Clin Cancer Res 19 2013 1920 1925
6. M. Clauss, H. Weich, G. Breier, U. Knies, W. Rockl, and J. Waltenberger et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis J Biol Chem 271 1996 17629 17634
7. S. De Falco, B. Gigante, and M.G. Persico Structure and function of placental growth factor Trends Cardiovasc Med 12 2002 241 246
8. S. De Falco The discovery of placenta growth factor and its biological activity Exp Mol Med 44 2012 1 9
9. S. De Falco Antiangiogenesis therapy: an update after the first decade Korean J Intern Med 29 2014 1 11
10. J.M. Ebos, and R.S. Kerbel Antiangiogenic therapy: impact on invasion, disease progression, and metastasis Nat Rev Clin Oncol 8 2011 210 221
11. N. Ferrara, and W.J. Henzel Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells Biochem Biophys Res Commun 161 1989 851 858
12. N. Ferrara, R.D. Mass, C. Campa, and R. Kim Targeting VEGF-A to treat cancer and age-related macular degeneration Annu Rev Med 58 2007 491 504
13. J. Folkman Angiogenesis: an organizing principle for drug discovery Nat Rev Drug Discov 6 2007 273 286
14. J.A. Forsythe, B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, and R.D. Koos et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 Mol Cell Biol 16 1996 4604 4613
15. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, and L.E. Abrey et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
16. K.P. Garnock-Jones Ranibizumab: in macular oedema following retinal vein occlusion Drugs 71 2011 455 463
17. K.J. Gotink, and H.M. Verheul Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action Angiogenesis 13 2010 1 14
18. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr., M. Feinsod, D.R. Guyer, and Group VISiONCT Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
19. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
20. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
21. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
22. D.F. Martin, M.G. Maguire, G.S. Ying, J.E. Grunwald, S.L. Fine, and G.J. Jaffe Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
23. K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, and E.A. Perez et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
24. H.A. Mintz-Hittner, K.A. Kennedy, A.Z. Chuang, and B-R.C. Group Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 2011 603 615
25. M. Muramatsu, S. Yamamoto, T. Osawa, and M. Shibuya Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth Cancer Res 70 2010 8211 8221
26. M. Potente, H. Gerhardt, and P. Carmeliet Basic and therapeutic aspects of angiogenesis Cell 146 2011 873 887
27. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, and C.Y. Chung et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
28. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
29. K. Sayanagi, S. Sharma, and P.K. Kaiser Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration Br J Ophthalmol 93 2009 622 626
30. U. Schmidt-Erfurth, P.K. Kaiser, J.F. Korobelnik, D.M. Brown, V. Chong, and Q.D. Nguyen et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 2013 193 201
31. G.L. Semenza HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus Cell 107 2001 1 3
32. B. Sennino, and D.M. McDonald Controlling escape from angiogenesis inhibitors Nat Rev Cancer 12 2012 699 709
33. S. Tugues, S. Koch, L. Gualandi, X. Li, and L. Claesson-Welsh Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer Mol Aspects Med 32 2011 88 111
34. S. Verma, D. McLeod, G. Batist, A. Robidoux, I.R. Martins, and J.R. Mackey In the end what matters most? A review of clinical endpoints in advanced breast cancer Oncologist 16 2011 25 35
35. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, and S.L. Topalian et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
36. Y. Yodoi, A. Tsujikawa, H. Nakanishi, A. Otani, H. Tamura, and Y. Ojima et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization Am J Ophthalmol 147 2009 816 824 24 e1